Institute of Medicine’s National Cancer Policy Forum Holds a Workshop on Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer
ASH staff recently attended an IOM National Cancer Policy Forum workshop on policy issues in the development and adoption of molecularly targeted therapies for cancer. The purpose of this workshop was to examine the recent trends in the development and implementation of molecularly targeted cancer therapies, address current challenges in the field, and to put forth potential strategies and policy action items that could improve current processes.
2014 ASH Advocacy Efforts Related to Sickle Cell Disease
ASH remains committed to working with various groups
in the sickle cell stakeholder community, Congress, the National Institutes of
Health (NIH), the Centers for Disease Control and Prevention (CDC), and other
federal agencies to increase research, treatment options, and access to care
for patients with sickle cell disease and sickle cell trait. Continue reading about the major initiatives
undertaken by the Society in 2014.
2014 ASH Advocacy Efforts to Ensure Access to Safe and Effective Hematologic Drugs
Over the past several years, shortages of drugs and
biologics used to treat patients with hematologic diseases, including leukemia
and lymphoma, have become critical and life-threatening. ASH has taken a number of steps to resolve
these drug and biologic shortages, including working with manufacturers, the
Food & Drug Administration (FDA) and Congress. ASH continues to be actively involved in this
issue. Continue reading for a summary of recent ASH advocacy efforts to address
drug and biologic shortages.
2014 NIH Funding Advocacy Highlights
During 2014, ASH has
continued to be one of the most visible advocates for federal support of
biomedical research and funding for the National Institutes of Health (NIH). Continue reading for a summary of ASH's 2014 advocacy efforts.